Table 5.
The most common (≥ 10%) TEAEs in the safety analysis set
| Ixazomib + LenDex N = 34 n (%) |
|
|---|---|
| Patients with at least 1 AE | 34 (100) |
| Constipation | 17 (50) |
| Upper respiratory tract infection | 16 (47) |
| Diarrhea | 14 (41) |
| Rash | 12 (35) |
| Nasopharyngitis | 11 (32) |
| Nausea | 10 (29) |
| Platelet count decreased | 9 (26) |
| Influenza | 8 (24) |
| Neutropenia | 8 (24) |
| Chilblains | 7 (21) |
| Dysgeusia | 7 (21) |
| Fall | 7 (21) |
| Peripheral sensory neuropathy | 7 (21) |
| Bronchitis | 6 (18) |
| Neutrophil count decreased | 6 (18) |
| Dental caries | 5 (15) |
| Malaise | 5 (15) |
| Edema peripheral | 5 (15) |
| Pharyngitis | 5 (15) |
| Maculopapular rash | 5 (15) |
| Vomiting | 5 (15) |
| Back pain | 4 (12) |
| Dry skin | 4 (12) |
| Hyperglycemia | 4 (12) |
| Oropharyngeal pain | 4 (12) |
| Pain in extremity | 4 (12) |
| Pneumonia | 4 (12) |
| Pyrexia | 4 (12) |
| Stomatitis | 4 (12) |
| Thrombocytopenia | 4 (12) |
| Urticaria | 4 (12) |
AE adverse event, LenDex lenalidomide and dexamethasone, TEAE treatment-emergent adverse event